Company intelligence / Profile preview

TruLeaf Medical

Caesarea, Israel

Ownership: Private
Employees: ~9
Development stage: Other

Overview

TruLeaf Medical has completed R&D and long-term animal testing for its RoseDoc transcatheter mitral valve replacement (TMVR) platform, with approval received for the first-in-human clinical trial. The system allows minimally invasive replacement of the mitral valve for patients with severe mitral regurgitation, aiming to address a major unmet need for those inoperable by standard surgery. Preclinical studies demonstrated successful elimination of valve leak and improved cardiac function.

Therapeutic areas: Cardiovascular
Modalities: DeviceBiologic
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on TruLeaf Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TruLeaf Medical.

Explore the full profile